A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 11 Mar 2018
Price : $35 *
At a glance
- Drugs Tesevatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Kadmon Corporation
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2017 Status changed from active, no longer recruiting to discontinued.
- 29 Nov 2016 Planned primary completion date changed from 30 Sep 2016 to 1 Dec 2016.